Please email us at Sales@AmericanPharmaWholesale.com with our item No, NDC#,UPC#or best is product link. We are located in Oceanside, California. Search over 100,000 items by Name, Item No., NDC, UPC (without dashes) or by Mfg.Name.
Menu

RX ITEM-Reopro 10Mg/5Ml Vial 5Ml By J-O-M Pharm Services

vial , clear , clear  Reopro 10mg/5ml Vial 5ml JOM PharmaBRAND: REOPRO NDC: 57894-0200-01,57894020001 UPC: 3-57894-20001-7,357894200017 JOM PHARMAJOM PHARMAWant to do Research on this Med or need a large quantity? Email Details with quantity required to:sales@AmericanPharmaWholesale.comVisit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.vial , clear , clear  Reopro 10mg/5ml Vial 5ml JOM PharmaJOM PHARMA

RX ITEM-Reopro 10Mg/5Ml Vial 5Ml By J-O-M Pharm Services

$1617.82$1485.00

item No.:RX607234 NDC No.57894020001 UPC No.:357894200017 NDC No.57894-0200-01 57894-200-01 UPC/GTIN No.3-57894-20001-7 MPN 714001 Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,ResearchCo.,Uni.,VA,Vet & Wholesalers in scope of practice can order this RX item. Rx Item No.Rx607234 Reopro 10mg/5ml Vial 5ml by J-O-M PHARM SERVICES Item No.607234 NDC No.57894020001 57894020001 UPC No.357894-200

Have a question?

  Please click: Have a question? or email us at sales@AmericanPharmaWholesale.com for current price and availability.

REOPRO- abciximab injection, solution
Janssen Biotech, Inc.

For intravenous administration

DESCRIPTION:

Abciximab, ReoPro� , is the Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation. Abciximab also binds to the vitronectin (αv β3 ) receptor found on platelets and vessel wall endothelial and smooth muscle cells.



The chimeric 7E3 antibody is produced by continuous perfusion in mammalian cell culture. The 47,615 dalton Fab fragment is purified from cell culture supernatant by a series of steps involving specific viral inactivation and removal procedures, digestion with papain and column chromatography.

ReoPro� is a clear, colorless, sterile, non-pyrogenic solution for intravenous (IV) use. Each single use vial contains 2 mg/mL of Abciximab in a buffered solution (pH 7.2) of 0.01 M sodium phosphate, 0.15 M sodium chloride and 0.001% polysorbate 80 in Water for Injection. No preservatives are added.

CLINICAL PHARMACOLOGY:

General - Abciximab binds to the intact platelet GPIIb/IIIa receptor, which is a member of the integrin family of adhesion receptors and the major platelet surface receptor involved in platelet aggregation. Abciximab inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules to GPIIb/IIIa receptor sites on activated platelets. The mechanism of action is thought to involve steric hindrance and/or conformational effects to block access of large molecules to the receptor rather than direct interaction with the RGD (arginine-glycine-aspartic acid) binding site of GPIIb/IIIa.

Abciximab binds with similar affinity to the vitronectin receptor, also known as the αv β3 integrin. The vitronectin receptor mediates the procoagulant properties of platelets and the proliferative properties of vascular endothelial and smooth muscle cells. In in vitro studies using a model cell line derived from melanoma cells, Abciximab blocked αv β3 -mediated effects including cell adhesion (IC50 = 0.34 μg/mL). At concentrations which, in vitro , provide > 80% GPIIb/IIIa receptor blockade, but above the in vivo therapeutic range, Abciximab more effectively blocked the burst of thrombin generation that followed platelet activation than select comparator antibodies which inhibit GPIIb/IIIa alone (1). The relationship of these in vitro data to clinical efficacy is unknown.

Abciximab also binds to the activated Mac-1 receptor on monocytes and neutrophils (2). In in vitro studies, Abciximab and 7E3 IgG blocked Mac-1 receptor function as evidenced by inhibition of monocyte adhesion (3). In addition, the degree of activated Mac-1 expression on circulating leukocytes and the numbers of circulating leukocyte-platelet complexes has been shown to be reduced in patients treated with Abciximab compared to control patients (4). The relationship of these in vitro data to clinical efficacy is uncertain.
INDICATIONS AND USAGE:

Abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications

in patients undergoing percutaneous coronary intervention
in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours

vial , clear , clear  Reopro 10mg/5ml Vial 5ml JOM Pharma
57894-0200-01
vial , clear , clear Reopro 10mg/5ml Vial 5ml JOM Pharma

BRAND: REOPRO NDC: 57894-0200-01,57894020001 UPC: 3-57894-20001-7,357894200017 JOM PHARMA
Reopro 10Mg/5Ml Vial 5Ml By J-O-M Pharm
BRAND: REOPRO NDC: 57894-0200-01,57894020001 UPC: 3-57894-20001-7,357894200017 JOM PHARMA

JOM PHARMA
JOM PHARMA
JOM PHARMA

Want to do Research on this Med or need a large quantity? Email Details with quantity required to:sales@AmericanPharmaWholesale.com
Buy More Save More!
Want to do Research on this Med or need a large quantity? Email Details with quantity required to:sales@AmericanPharmaWholesale.com

Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.
AmericanPharmaWholesale.com
Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.

vial , clear , clear  Reopro 10mg/5ml Vial 5ml JOM Pharma
RX ITEM-Reopro 10Mg/5Ml Vial 5Ml By J-O-
vial , clear , clear Reopro 10mg/5ml Vial 5ml JOM Pharma

JOM PHARMA
JOM PHARMA
JOM PHARMA